Drug Trial Radar · NCT05682482
LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.
Last checked: Nov 20, 2026Latest source record: Feb 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Oct 7, 2022
Primary completion
Jan 2028
Study completion Jan 2028
Sponsor
- Lead sponsor
- M. MediciAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ZonMw: The Netherlands Organisation for Health Research and Development; ACE Pharmaceuticals BV
- First posted
- Jan 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hypothyroidism is common, affecting 5% of the general population, for which levothyroxine (LT4) monotherapy is the standard treatment. Despite normalized serum thyroid hormone levels, 10-15% of LT4 treated patients have various persistent complaints, the most important of which is tiredness. This could be explained by the fact that physiological T4/T3 ratios cannot be reached with LT4 monotherapy, as in a healthy individual T3 is not only derived from T4/T3 conversion but is also directly produced by the thyroid itself. Studies have reported contradicting results as to whether addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy is effective or not. Studies have suggested higher effectiveness in patients carrying genetic variation in the type 2 deiodinase (DIO2-rs225014) and monocarboxylate transporter 10 (MCT10-rs17606253) genes. Objective: To investigate whether addition of liothyronine (LT4/LT3 combination therapy) in in patients with persistent tiredness on LT4 monotherapy is effective or not in relieving tiredness.
Conditions
- Autoimmune Hypothyroidism
Interventions
LT3 (liothyronine)Drug
Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.
PlaceboDrug
Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline to 52 weeks in the ThyPRO tiredness subscale scores.Time frame: 52 weeks
- Effect sizes in genetic subgroupsTime frame: 52 weeks
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Flevoziekenhuis
Almere Stad, Netherlands · Recruiting
Amsterdam UMC - Location AMC
Amsterdam, Netherlands · Recruiting
Gelre ziekenhuizen
Apeldoorn, Netherlands · Not yet recruiting
Rijnstate
Arnhem, Netherlands · Recruiting
Amphia ziekenhuis
Breda, Netherlands · Recruiting
Van Weel-Bethesda Hospital
Dirksland, Netherlands · Recruiting
Albert Schweitzer Hospital
Dordrecht, Netherlands · Recruiting
Treant
Emmen, Netherlands · Not yet recruiting
Admiraal de Ruyter Hospital
Goes, Netherlands · Recruiting
University Medical Center Groningen
Groningen, Netherlands · Recruiting
Saxenburgh MC
Hardenberg, Netherlands · Recruiting
Radboudumc
Nijmegen, Netherlands · Recruiting
Erasmus Medical Center
Rotterdam, Netherlands · Recruiting
Maasstad Hospital
Rotterdam, Netherlands · Recruiting
Franciscus Gasthuis & Vlietland
Schiedam, Netherlands · Recruiting
Zuyderland
Sittard, Netherlands · Recruiting
University Medical Center Utrecht
Utrecht, Netherlands · Recruiting
Maxima Medical Center
Veldhoven, Netherlands · Recruiting
Vie Curie MC
Venlo, Netherlands · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.